Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort
Open Access
- 8 July 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-14
Abstract
The efficacy and treatment outcome of a CML patient are heavily dependent on BCR::ABL1 kinase domain (KD) mutation status. Next-generation sequencing technology is a bright alternative to the previously used sanger sequencing method due to its global presence in diagnostic setups, massive parallel sequencing ability, and far better sensitivity. In the present study, we have demonstrated a new protocol for kinase domain mutation analysis using the next-generation sequencing (NGS) method using the ion torrent sequencing platform. This protocol uses RNA as the starting material, followed by nested PCR to amplify the fusion transcript, which is subsequently used as a template for NGS. Initial validation and comparison of this assay with the sanger sequencing (SS) method yielded 95.23% agreement. CML samples (n = 121) with a failure to TKI response were subjected to this newly developed NGS-based assay to detect KD mutations, from which samples were found to have mutations with a sensitivity ranging from 2.32 to 93.41%. A total of 34.71% of samples (n = 42) were found to be positive for one or more KD mutations, whereas 65.29% of samples (n = 81) were found to be negative. Nine samples out of 42 positive samples, i.e., 21.42%, were found to have compound mutations. This is one of the first studies from India, which includes more than 160 samples and is analyzed by the NGS approach for KD mutation analysis.Keywords
This publication has 57 references indexed in Scilit:
- Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian PopulationIndian Journal of Hematology and Blood Transfusion, 2024
- Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencingAnnals of Hematology, 2015
- Evaluation of Hybridization Capture Versus Amplicon‐Based Methods for Whole‐Exome SequencingHuman Mutation, 2015
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer ScreeningThoracic Surgery Clinics, 2015
- Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phaseJournal of Cancer Research and Clinical Oncology, 2014
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaCancer Cell, 2014
- Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencingEuropean Journal of Cancer, 2014
- Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshopAmerican Journal of Hematology, 2011
- Not all imatinib resistance in CML are BCR-ABL kinase domain mutationsAnnals of Hematology, 2006
- BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyThe Lancet, 2002